DK3242678T3 - Kombinationspræparater til behandling af cancer eller infektion - Google Patents

Kombinationspræparater til behandling af cancer eller infektion Download PDF

Info

Publication number
DK3242678T3
DK3242678T3 DK16700138.7T DK16700138T DK3242678T3 DK 3242678 T3 DK3242678 T3 DK 3242678T3 DK 16700138 T DK16700138 T DK 16700138T DK 3242678 T3 DK3242678 T3 DK 3242678T3
Authority
DK
Denmark
Prior art keywords
lag
virus
protein
derivative
cancer
Prior art date
Application number
DK16700138.7T
Other languages
English (en)
Inventor
Frédéric Triebel
Chrystelle Brignone
Original Assignee
Immutep Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immutep Sas filed Critical Immutep Sas
Application granted granted Critical
Publication of DK3242678T3 publication Critical patent/DK3242678T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)

Claims (17)

1. Kombinationspræparat, der omfatter: (a) LAG-3-protein, eller et derivat deraf, der kan binde til MHC-klasse-II-molekyler, hvor derivatet af LAG-3-protein omfatter en aminosyresekvens, der har mindst 70 % aminosyreidentitet med domæne Dl, og eventuelt domæne D2, af LAG-3-protein, eller hvor derivatet af LAG-3-protein omfatter en aminosyresekvens, der har mindst 70 % aminosyreidentitet med domænerne Dl, D2, D3, og eventuelt D4, af LAG-3-protein; og (b) en programmeret celledødsprotein-1- (PD-1) banehæmmer, hvor PD-1-banehæmmeren omfatter et anti-PD-1-antistof, eller et derivat eller fragment deraf, der bevarer evne til at hæmme binding af PD-1 til PD-L1 og/eller PD-L2, eller hvor PD-1-banehæmmeren omfatter et anti-PD-Ll-antistof, eller et derivat eller fragment deraf, der bevarer evne til at hæmme binding af PD-L1 til PD-1.
2. Farmaceutisk sammensætning, der omfatter: (a) LAG-3-protein, eller et derivat deraf, der kan binde til MHC-klasse-II-molekyler, hvor derivatet af LAG-3-protein omfatter en aminosyresekvens, der har mindst 70 % aminosyreidentitet med domain Dl, og eventuelt domæne D2, af LAG-3-protein, eller hvor derivatet af LAG-3-protein omfatter en aminosyresekvens, der har mindst 70 % aminosyreidentitet med domænerne Dl, D2, D3, og eventuelt D4, af LAG-3-protein; (b) en PD-1-banehæmmer, hvor PD-l-banehæmmeren omfatter et anti-PD-1-antistof, eller et derivat eller fragment deraf, der bevarer evne til at hæmme binding af PD-1 til PD-L1 og/eller PD-L2, eller hvor PD-l-banehæmmeren omfatter et anti-PD-Ll-antistof, eller et derivat eller fragment deraf, der bevarer evne til at hæmme binding af PD-L1 til PD-1; og (c) en farmaceutisk acceptabel bærer, excipiens eller fortynder.
3. Kombinationspræparat ifølge krav 1, eller farmaceutisk sammensætning ifølge krav 2, til coadministration eller sekventiel administration af LAG-3-proteinet, eller et derivat deraf, og PD-1 -banehæmmeren.
4. Kombinationspræparat eller farmaceutisk sammensætning ifølge et hvilket som helst foregående krav, hvor LAG-3-proteinet, eller et derivat deraf, er adskilt fra PD-1- banehæmmeren.
5. Kombinationspræparat eller farmaceutisk sammensætning ifølge et hvilket som helst foregående krav, hvor LAG-3-proteinet, eller et derivat deraf, er til stede i en dosis, der er en molækvivalent af 0,25-30 mg af LAG-3 Ig-fusionsprotein IMP321.
6. Kombinationspræparat eller farmaceutisk sammensætning ifølge et hvilket som helst foregående krav, der omfatter en flerhed af doser af LAG-3-proteinet, eller et derivat deraf og/eller en flerhed af doser af PD-1-banehæmmeren.
7. Kombinationspræparat eller farmaceutisk sammensætning ifølge et hvilket som helst foregående krav, hvor PD-1-banehæmmeren omfatter: et anti-PD-1 -antistof, eller et derivat eller fragment deraf, der bevarer evne til at hæmme binding af PD-1 til PD-L1 og/eller PD-L2, og hvor PD-1-banehæmmeren er pembrolizumab eller nivolumab eller pidilizumab; eller et anti-PD-Ll-antistof, eller et derivat eller fragment deraf, der bevarer evne til at hæmme binding af PD-L1 til PD-1, og hvor PD-1-banehæmmeren er BMS-936559, MED14736, MPDL3280A eller MSB0010718C.
8. Kombinationspræparat eller farmaceutisk sammensætning ifølge et hvilket som helst foregående krav, hvor PD-1-banehæmmeren er til stede ved en dosis, der er op til 50 %, 1-50 %, 1-25 %, eller 1-10 %, af en typisk ordineret dosis af PD-1-banehæmmeren som en monoterapi, eller hvor PD-1-banehæmmeren er til stede ved en dosis, der er 0,1-50 %, 0,1-25 %, 0,1-20 %, 0,1-10 %, <20 %, <10 %, 0,1-<20 %, 0, l-<10 %, 0,01-<20 % eller 0,01-<10 % af en typisk ordineret dosis af PD-1-banehæmmeren som en monoterapi.
9. Kombinationspræparat eller farmaceutisk sammensætning ifølge et hvilket som helst foregående krav, hvor LAG-3-proteinet eller et derivat deraf, og PD-1-banehæmmeren, er til stede i en hvilken som helst af kombinationerne af de doseringsmængder, der vises i nedenstående tabel:
10. Kombinationspræparat eller farmaceutisk sammensætning ifølge et hvilket som helst foregående krav, hvor derivatet af LAG-3-protein omfatter en aminosyresekvens, der har mindst 70 % aminosyreidentitet med domæne Dl, og eventuelt domæne D2, af humant LAG-3-protein, eller hvor derivatet af LAG-3-protein omfatter en aminosyresekvens, der har mindst 70 % aminosyreidentitet med domænerne Dl, D2, D3, og eventuelt D4, af humant LAG-3-protein.
11. Kombinationspræparat eller farmaceutisk sammensætning ifølge et hvilket som helst foregående krav, hvor derivatet af LAG-3-protein er kondenseret til immunoglobulin Fc-sekvensen, fortrinsvis hvor derivatet af LAG-3-protein er det rekombinante opløselige humane LAG-3Ig-fusionsprotein IMP321.
12. Kombinationspræparat eller a farmaceutisk sammensætning ifølge et hvilket som helst af følgende krav til anvendelse som et medikament.
13. Kombinationspræparat eller farmaceutisk sammensætning ifølge et hvilket som helst af kravene 1 til 11 til anvendelse i forebyggelse, behandling eller bedring af cancer.
14. Kombinationspræparat eller farmaceutisk sammensætning til anvendelse ifølge krav 13, hvor canceren er en PD-L1-positiv eller en PD-L2-positiv cancer, eller hvor canceren er hud-, lunge- (navnlig pladeepitel- eller ikke-pladeepitel- ikke-småcellet lungekarcinom, NSCLC), ovarie-, nyre-, colon-, kolorektal-, bryst-, gastrisk, øsofagus-, pankreas-, blære-, urotelial- eller levercancer, eller et melanom (for eksempel, metastatisk malignt melanom), en prostatacancer (for eksempel hormonrefraktært prostataadenokarcinom), cancer i hoved eller hals (for eksempel pladeepitelkarcinom i hoved og hals), en cervixcancer, en thyroideacancer, et glioblastom, et gliom, leukæmi, et lymfom (for eksempel, et B-cellelymfom), en binyrecancer, en aids-associeret cancer, et alveolært bløddelssarkom, en astrocytisk tumor, knoglecancer, en cancer i hjerne og rygmarv, en metastatisk hjernetumor, en karotidlegemetumor, et chondrosarkom, et chordom, et kromofobt nyrecellekarcinom, et spytkirtelkarcinom, kutant benignt fibrøst histiocytom, en desmoplastisk småcellet rund tumor, et ependymom, en Ewings tumor, et ekstraskeletalt myksoidt chondrosarkom, fibrogenesis imperfecta ossium, fibrøst knogledysplasi, en gæIdeblære- eller galdevejscancer, en gestational trofoblastisk sygdom, en kimcelletumor, en hæmatologisk malignitet, et hepatocellulært karcinom, en øcelletumor, et Kaposis sarkom, en nyrecancer, et lipom/en benign lipomatøs tumor, et liposarkom/en malign lipomatøs tumor, et medulloblastom, et meningiom, et Merkelcellekarcinom, en multipel endokrin neoplasi, et multiplet myelom, et myelodysplasisyndrom, et neuroblastom, en neuroendokrin tumor, et papillært thyroideakarcinom, et parathyroideatumor, en pædiatrisk cancer, en perifer nerveskedetumor, et phæochromocytom, en hypofysetumor, en prostatacancer, et posteriori uvealt melanom, en sjælden hæmatologisk forstyrrelse, en metastatisk nyrecancer, en rhabdoid tumor, et rhabdomysarkom, et sarkom, et blødvævssarkom, en pladeepitelcancer, en mavecancer, et synovialsarkom, en testiscancer, et thymuskarcinom, et thymom, en metastatisk thyreoideacancer eller en uteruscancer.
15. Kombinationspræparat eller farmaceutisk sammensætning ifølge et hvilket som helst af kravene 1 til 11 til anvendelse i forebyggelse, behandling eller bedring af en infektion.
16. Kombinationspræparat til anvendelse ifølge krav 15, hvor infektionen er en kronisk eller vedvarende infektion.
17. Kombinationspræparat til anvendelse ifølge krav 15 eller 16, hvor infektionen er en virus-, bakterie-, svampe- eller protozoinfektion, fortrinsvis hvor virusinfektionen er forårsaget af et adenovirus, et adenoassocieret virus, et B-virus (macacine herpesvirus I), et BK-virus, et bunyavirus, et chikungunya-virus, et cocksackie-virus, et coronavirus, et cytomegalovirus, et østligt hesteencephalitis-virus, et ebolavirus, et enterovirus, et Epstein-Barr-virus, et hantavirus, et hepatitis A-virus, et hepatitis B-virus, et hepatitis C-virus, et hepatitis D-virus, et hepatitis E-virus, et herpesvirus, et herpes simplex virus 1, et herpes simplex virus 2, et humant spumavirus, et humant herpesvirus 3, et humant herpesvirus 5, et humant herpesvirus 6, et humant herpesvirus 7, et humant immundefektvirus, et humant papillomavirus, et humant β-lymfotrofisk virus, et humant T-celle-leukæmivirus I, et humant T-celle-leukæmivirus II, et influenzavirus, et JC-virus, et JEV, et Kaposis sarkom-associeret herpesvirus, et Lassa-virus, et lymfocytisk choriomeningitisvirus, et Marburg-virus, et mæslingevirus, et fåresygevirus, et Nipah-virus, et norovirus, et Norwalk-virus, et orthoreovirus, et parainfluenzavirus, et parvovirus, et poliovirus, et rabiesvirus, et reovirus, et respiratorisk syncytialvirus, rhinovirus, et Rift Valley-febervirus, et rotavirus, rubellavirus, et koppervirus, et St Louis encephalitisvirus, et variola major virus, et variola minor virus, et vericella-zoster-virus, et vestnilvirus, et vestligt hesteencephalitis-virus eller et gul febervirus, eller hvor bakterieinfektionen er forårsaget af Escherichia coli, Clostridium difficile, Salmonella thyphimurium, Pseudomonas aeruginosa, Vibrio cholerae, Neisseria gonorrhoeae, Helicobacter pylori, Hemophilus influenzae, Shigella dysenteriae, Staphylococcus aureus, Mycobacterium tuberculosis, Streptococcus pneumonia eller Chlamydia trachomatis, eller hvor svampeinfektionen er forårsaget af Candida, Aspergillus, Cryptococcus, Coccidioides, Histoplasma, Pneumocystis, eller Stachybotrys, eller hvor protozoinfektionen er forårsaget af Amoebozoa, Excavata, Chromalveolata, Entamoeba, Plasmodium, Giardia, Trypanosoma, Coccidia, Besnoitia, Dicrocoelium eller Leishmania.
DK16700138.7T 2015-01-09 2016-01-08 Kombinationspræparater til behandling af cancer eller infektion DK3242678T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1500374.2A GB201500374D0 (en) 2015-01-09 2015-01-09 Combined preparations for the treatment of cancer
PCT/EP2016/050321 WO2016110593A1 (en) 2015-01-09 2016-01-08 Combined preparations for the treatment of cancer or infection

Publications (1)

Publication Number Publication Date
DK3242678T3 true DK3242678T3 (da) 2019-03-11

Family

ID=52597438

Family Applications (2)

Application Number Title Priority Date Filing Date
DK16700138.7T DK3242678T3 (da) 2015-01-09 2016-01-08 Kombinationspræparater til behandling af cancer eller infektion
DK18208378.2T DK3473263T3 (da) 2015-01-09 2016-01-08 Kombinerede præparater til behandling af kræft

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK18208378.2T DK3473263T3 (da) 2015-01-09 2016-01-08 Kombinerede præparater til behandling af kræft

Country Status (21)

Country Link
US (5) US10874713B2 (da)
EP (3) EP3473263B1 (da)
JP (5) JP7116547B2 (da)
KR (2) KR102704108B1 (da)
CN (2) CN114146161A (da)
AU (3) AU2016205983B2 (da)
CA (1) CA2973044A1 (da)
CY (1) CY1124462T1 (da)
DK (2) DK3242678T3 (da)
ES (2) ES2704272T3 (da)
GB (1) GB201500374D0 (da)
HR (1) HRP20211346T1 (da)
HU (1) HUE055433T2 (da)
IL (1) IL253243A0 (da)
LT (1) LT3473263T (da)
MX (2) MX387326B (da)
PL (2) PL3473263T3 (da)
PT (2) PT3242678T (da)
SI (1) SI3473263T1 (da)
TR (1) TR201901077T4 (da)
WO (1) WO2016110593A1 (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
HUE046249T2 (hu) 2013-12-12 2020-02-28 Shanghai hengrui pharmaceutical co ltd PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
CA2991976A1 (en) 2015-07-13 2017-01-19 Cytomx Therapeutics, Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
MY199705A (en) * 2015-12-22 2023-11-20 Incyte Corp Heterocyclic compounds as immunomodulators
CN109843924A (zh) * 2016-09-06 2019-06-04 梅约医学教育与研究基金会 治疗表达pd-l1的癌症的方法
CA3047991A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
KR102721137B1 (ko) 2017-05-30 2024-10-25 브리스톨-마이어스 스큅 컴퍼니 항-lag-3 항체 또는 항-lag-3 항체 및 항-pd-1 또는 항-pd-l1 항체를 포함하는 조성물
CA3060984A1 (en) 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Treatment of lag-3 positive tumors
EP3768727A4 (en) * 2018-03-20 2021-12-22 Wuxi Biologics Ireland Limited. NEW BIS SPECIFIC PD-1 / LAG-3 ANTIBODY MOLECULES
EP3826660A1 (en) * 2018-07-26 2021-06-02 Bristol-Myers Squibb Company Lag-3 combination therapy for the treatment of cancer
US20220211715A1 (en) * 2019-05-22 2022-07-07 Agency For Science, Technology And Research Pharmaceutical combination
JP2022537162A (ja) * 2019-06-14 2022-08-24 ジー・テック・バイオ・エルエルシー 活性化リンパ球細胞ならびにそれを使用してがん及び感染状態を治療する方法
EP4037663A1 (en) 2019-10-03 2022-08-10 Starton Therapeutics, Inc. Transdermal delivery of dronabinol
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
CN110938691B (zh) * 2019-12-03 2023-07-07 兰州大学 人dus4l基因的用途及相关产品
CN110950966B (zh) * 2019-12-13 2020-12-11 启辰生生物科技(珠海)有限公司 融合蛋白、编码核酸和细胞及用途
US20230210946A1 (en) * 2020-05-28 2023-07-06 Immutep S.A.S. Treatment of cancer
US20240101666A1 (en) 2020-10-23 2024-03-28 Bristol-Myers Squibb Company Lag-3 antagonist therapy for lung cancer
GB202108718D0 (en) 2021-06-18 2021-08-04 Immutep Sas Triple combination therapy
TWI866210B (zh) 2022-05-17 2024-12-11 大陸商蘇州創勝醫藥集團有限公司 雙功能蛋白質及其製劑和用途

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
US5098702A (en) 1986-04-09 1992-03-24 Cetus Corporation Combination therapy using interleukin-2 and tumor necrosis factor
CA1341281C (en) 1986-07-09 2001-08-07 Hubert J.P. Schoemaker Immunotherapy of tumor with monoclonal antibody against the 17-1a antigen
US5785973A (en) 1988-02-01 1998-07-28 Praxis Biologics, Inc. Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
JP3082204B2 (ja) 1988-09-01 2000-08-28 ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ 両栄養性および環境栄養性宿主域を持つ組換え体レトロウイルス
US5665577A (en) 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
DE69020143T2 (de) 1989-02-17 1996-01-25 Chiron Mimotopes Pty Ltd Verfahren zur verwendung und herstellung von peptiden.
US5266491A (en) 1989-03-14 1993-11-30 Mochida Pharmaceutical Co., Ltd. DNA fragment and expression plasmid containing the DNA fragment
JP3051411B2 (ja) 1989-03-14 2000-06-12 持田製薬株式会社 新規ｄｎａならびにそれを含有する発現プラスミド
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US5976877A (en) 1990-01-08 1999-11-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses
FR2656800B1 (fr) 1990-01-08 1992-05-15 Roussy Inst Gustave Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.
US7294712B2 (en) 1990-06-04 2007-11-13 Aventis Pharma S.A. Nucleotide sequences coding for variable regions of β chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses
US5981276A (en) 1990-06-20 1999-11-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
DK0551401T3 (da) 1990-09-14 1996-01-22 Univ Texas Fremgangsmåde og præparater til genterapi og potensering af antitumor-immunitet
JP3459268B2 (ja) 1990-09-17 2003-10-20 中外製薬株式会社 抗癌剤
EP0529033B1 (fr) 1991-02-08 2006-08-30 Aventis Pharma S.A. Sequences nucleotidiques codant pour des regions variables de chaines alpha des recepteurs des lymphocytes humains ainsi que leurs applications
US6596536B1 (en) 1991-02-08 2003-07-22 Aventis Pharma S.A. Nucleotide sequences coding for variable regions of the alpha chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses
KR100227303B1 (ko) 1991-02-12 1999-12-01 장-끌로드 비에이으포스 인체 t 임파구 수용체의 베타 사슬의 가변성 영역을 코딩하는 뉴클레오티드 서열, 대응하는 펩티드 세그먼트 및 진단 및 치료 용도
US5904920A (en) 1991-10-04 1999-05-18 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens
US5637483A (en) 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
US6506604B2 (en) 1993-06-11 2003-01-14 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
DK0758383T3 (da) 1994-05-06 2007-05-29 Roussy Inst Gustave Oplöselige polypeptidfraktioner af LAG-3-proteinet; fremgangsmåde til fremstilling; terapeutisk sammensætning; antiidiotypisk antistof
US5872005A (en) 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
US6040183A (en) 1995-06-07 2000-03-21 University Of North Carloina At Chapel Hill Helper virus-free AAV production
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
US6033674A (en) 1995-12-28 2000-03-07 Johns Hopkins University School Of Medicine Method of treating cancer with a tumor cell line having modified cytokine expression
US5840839A (en) 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US6277368B1 (en) 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
US6482925B1 (en) 1996-11-28 2002-11-19 Applied Research Systems Ars Holding N.V. Mutants of the LAG-3 proteins and nucleotides encoding LAG-3 mutants
EP0941329B1 (en) 1996-11-29 2004-07-21 Applied Research Systems ARS Holding N.V. Methods for preventing graft rejection in transplantation and for producing a universal gene therapy host cell using lymphocyte activation (lag-3)
AU728220B2 (en) 1997-04-14 2001-01-04 Cell Genesys, Inc. Methods for increasing the efficiency of recombinant AAV product
EP0893507A1 (en) * 1997-07-25 1999-01-27 Institut Gustave Roussy Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment
US6037177A (en) 1997-08-08 2000-03-14 Cell Genesys, Inc. Method for increasing the efficiency of recombinant AAV production
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
CA2318372C (en) 1998-02-02 2008-08-19 Johns Hopkins University School Of Medicine A universal immunomodulatory cytokine-expressing bystander cell line and related compositions and methods of manufacture and use
FR2777890B1 (fr) 1998-04-22 2000-12-29 Roussy Inst Gustave Composes peptidiques d'hsp70 utiles dans l'immunotherapie du cancer
AU5458500A (en) 1999-06-02 2000-12-18 Cell Genesys, Inc. Regulation of systemic immune responses utilizing cytokines and antigens
AU5544500A (en) 1999-06-15 2001-01-02 Astrazeneca Ab Livin; inhibitor-of-apoptosis protein-3 (iap-3)
FR2795415B1 (fr) 1999-06-28 2003-09-05 Roussy Inst Gustave Compose peptidique derive d'une orf decalee du gene ice
AT409086B (de) 1999-11-16 2002-05-27 Igeneon Krebs Immuntherapie Neue verwendung von antikörpern als impfstoffe
EP1276468A1 (fr) 2000-04-26 2003-01-22 Biovector Therapeutics S.A. Utilisation de vecteurs particulaires dans l' immunomodulation
US7919467B2 (en) 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
EP1295895B1 (en) 2001-09-19 2011-08-10 Institut Gustave Roussy Peptides and proteins binding to glu-pro motifs, therapeutical compositions containing the same and applications thereof
EP2272513A1 (en) 2002-05-17 2011-01-12 Celgene Corporation Pharmaceutical compositions for treating cancer
PT1537878E (pt) 2002-07-03 2010-11-18 Ono Pharmaceutical Co Composições de imunopotenciação
US7439042B2 (en) 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
US20040197312A1 (en) 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
SG146662A1 (en) 2003-10-10 2008-10-30 Powderject Vaccines Inc Method
FR2868781B1 (fr) 2004-04-13 2008-02-22 Immutep Composition de vaccin comprenant un ligand cmh de classe ii couple a un antigene, procede de preparation et utilisations
JP2006124383A (ja) 2004-09-30 2006-05-18 Kobayashi Pharmaceut Co Ltd 樹状細胞活性化剤
JP2006141346A (ja) 2004-11-24 2006-06-08 Kobayashi Pharmaceut Co Ltd 樹状細胞活性化剤
US20070231298A1 (en) 2006-03-31 2007-10-04 Cell Genesys, Inc. Cytokine-expressing cancer immunotherapy combinations
US7919079B2 (en) 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
KR101586617B1 (ko) * 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
US8425897B2 (en) 2007-08-30 2013-04-23 Immutep S.A. Compositions containing LAG-3 and cells that secrete GM-CSF and methods of use
EP2044949A1 (en) * 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
AR072999A1 (es) * 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
WO2011082400A2 (en) * 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
US8907053B2 (en) * 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
CA2820384A1 (en) 2010-12-06 2012-06-14 Cure Cancer Worldwide Corporation Methods of metabolic targeting cancer cells using chemo- and immunotherapy for treating cancer
MX341076B (es) 2011-03-31 2016-08-04 Merck Sharp & Dohme Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
SG2014008304A (en) * 2012-02-01 2014-06-27 Compugen Ltd C10rf32 antibodies, and uses thereof for treatment of cancer
AU2013263076B2 (en) 2012-05-15 2017-08-31 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
US9308236B2 (en) * 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
WO2014194293A1 (en) 2013-05-30 2014-12-04 Amplimmune, Inc. Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof
AU2014323523B2 (en) 2013-09-20 2020-02-20 Bristol-Myers Squibb Company Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
CA2935423C (en) 2014-01-24 2023-11-07 Dana-Farber Cancer Institute, Inc. Antibody molecules to pd-1 and uses thereof
WO2015131176A1 (en) 2014-02-28 2015-09-03 Podack Eckhard R Compositions, methods, and kits for treatment of cancer
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer

Also Published As

Publication number Publication date
BR112017014742A2 (pt) 2018-02-06
PT3242678T (pt) 2019-02-04
PT3473263T (pt) 2021-08-26
ES2885901T3 (es) 2021-12-15
US20180271940A1 (en) 2018-09-27
EP3473263B1 (en) 2021-06-02
PL3242678T3 (pl) 2019-05-31
JP2025109795A (ja) 2025-07-25
RU2017127000A3 (da) 2019-07-30
LT3473263T (lt) 2021-09-27
JP2018506520A (ja) 2018-03-08
JP7565614B2 (ja) 2024-10-11
EP3943099A1 (en) 2022-01-26
US20230074746A1 (en) 2023-03-09
CN107249619A (zh) 2017-10-13
CN114146161A (zh) 2022-03-08
JP2024015265A (ja) 2024-02-01
NZ733726A (en) 2024-12-20
JP7116547B2 (ja) 2022-08-10
MX378860B (es) 2025-03-10
CN107249619B (zh) 2021-10-29
MX387326B (es) 2025-03-18
AU2016205983B2 (en) 2021-10-28
CY1124462T1 (el) 2021-12-31
US20200121757A1 (en) 2020-04-23
NZ771781A (en) 2024-12-20
RU2017127000A (ru) 2019-02-11
TR201901077T4 (tr) 2019-02-21
MX2017009003A (es) 2018-03-15
US20210177937A1 (en) 2021-06-17
SI3473263T1 (sl) 2022-01-31
MX2021000299A (es) 2021-10-26
KR20170120104A (ko) 2017-10-30
HRP20211346T1 (hr) 2021-11-26
US10874713B2 (en) 2020-12-29
WO2016110593A1 (en) 2016-07-14
IL253243A0 (en) 2017-08-31
AU2024204196A1 (en) 2024-07-11
JP2020073594A (ja) 2020-05-14
US10940181B2 (en) 2021-03-09
EP3242678A1 (en) 2017-11-15
HUE055433T2 (hu) 2021-11-29
US11684654B2 (en) 2023-06-27
CA2973044A1 (en) 2016-07-14
US20230330182A1 (en) 2023-10-19
JP2022118119A (ja) 2022-08-12
EP3473263A1 (en) 2019-04-24
ES2704272T3 (es) 2019-03-15
AU2016205983A1 (en) 2017-08-03
AU2022200133A1 (en) 2022-02-10
DK3473263T3 (da) 2021-09-06
KR102704108B1 (ko) 2024-09-10
KR20240122564A (ko) 2024-08-12
GB201500374D0 (en) 2015-02-25
PL3473263T3 (pl) 2021-12-13
EP3242678B1 (en) 2018-11-28

Similar Documents

Publication Publication Date Title
US11684654B2 (en) Combined preparations for the treatment of cancer or infection
Andrews et al. LAG 3 (CD 223) as a cancer immunotherapy target
Jacobs et al. Immune checkpoint modulation in colorectal cancer: what’s new and what to expect
Rolig et al. Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8+ T cell cytotoxicity over BEMPEG+ RT
HK40067473A (en) Combined preparations for the treatment of cancer or infection
RU2777945C2 (ru) Комбинированные препараты для лечения рака или инфекции
HK40006950B (en) Combined preparations for the treatment of cancer
HK40006950A (en) Combined preparations for the treatment of cancer or infection
NZ771781A9 (en) Combined preparations for the treatment of cancer or infection
NZ771781B2 (en) Combined preparations for the treatment of cancer or infection
HK1239550A1 (en) Combined preparations for the treatment of cancer or infection
HK1239550B (en) Combined preparations for the treatment of cancer or infection
Shen et al. Checkpoint inhibition and CAR T cells for the Treatment of Glioblastoma
BR122024006008B1 (pt) Uso de preparações combinadas e composições para a preparação de medicamento para o tratamento de infecção
BR112017014742B1 (pt) Preparações combinadas para o tratamento de câncer ou infecção
BR122024006008A2 (pt) Preparações combinadas para o tratamento de câncer ou infecção